This is a prospective, multicenter, non-interventional, single-arm, real-world study planned to be conducted in China, aimed at exploring the resistance mechanisms of first-line lorlatinib treatment in patients with ALK-positive locally advanced or metastatic NSCLC, as well as the efficacy and safety of sequential treatments following lorlatinib resistance in the real-world setting.
Age: Patients aged 18 years or older;
Histologically or cytologically confirmed locally advanced or metastatic NSCLC
Documened ALK resrrangemen by approved test (eg.. FisH,IHC. .r NGS).
first-line loelaninab treatment fom Apr2023-Apr-2027.
Previous treatment with other ALK-TKIs: Patients who have previously received any ALK TKI other than lorlatinib;
Concomitant medications: Patients who have received any systemic anti-tumor treatment other than lorlatinib before enrollment.